X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XFOR X4 Pharmaceuticals Inc

Trading 05-13 14:59:25 EDT

4.28

-0.06

-1.38%

High4.37	Low4.21	Vol158.39K
Open4.32	D1 Closing4.34	Amplitude3.57%
Mkt Cap403.69M	Tradable Cap290.83M	Total Shares94.32M
T/O683.13K	T/O Rate0.23%	Tradable Shares67.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XFOR","market":"US","secType":"STK","nameCN":"X4 Pharmaceuticals Inc","latestPrice":4.28,"timestamp":1778698764246,"preClose":4.34,"halted":0,"volume":158390,"delay":0,"changeRate":-0.013824884792626639,"floatShares":67951100,"shares":94319696,"eps":-4.6392,"marketStatus":"Trading","change":-0.06,"latestTime":"05-13 14:59:25 EDT","open":4.32,"high":4.365,"low":4.21,"amount":683126.360693,"amplitude":0.035714,"askPrice":4.29,"askSize":585,"bidPrice":4.27,"bidSize":114,"shortable":3,"etf":0,"ttmEps":-4.6392,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778702400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1510808400000,"exchange":"NASDAQ","adjPreClose":4.34,"preHourTrading":{"tag":"盘前","latestPrice":4.24,"preClose":4.34,"latestTime":"08:24 EDT","volume":111,"amount":480.6497913,"timestamp":1778675065061,"change":-0.1,"changeRate":-0.023041,"amplitude":0.023041},"postHourTrading":{"tag":"盘后","latestPrice":4.4,"preClose":4.34,"latestTime":"19:38 EDT","volume":1460,"amount":6351.52,"timestamp":1778629090074,"change":0.06,"changeRate":0.013825,"amplitude":0.013825},"volumeRatio":0.414059,"impliedVol":0.72,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/XFOR/wiki","defaultTab":"wiki","newsList":[{"id":"2635240902","title":"X4 Pharmaceuticals shareholders approved amended 2017 equity incentive plan share increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240902","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240902?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:24","pubTimestamp":1778617479,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals held its annual meeting on March 20, 2026.Stockholders authorized an increase of 1,500,000 shares available for issuance under Second Amended and Restated 2017 Equity Incentive Plan; authorization does not by itself indicate any shares have been issued.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8F0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633013150","title":"BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633013150","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633013150?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:13","pubTimestamp":1778102037,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC FilingX4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS INC - MAY OFFER UP TO $300 MILLION OF COMMON STOCK, PREFERRED STOCK, DEBT SECURITIES, WARRANTS, AND/OR UNITS - SEC FILINGSource text: [ID:n0001501697-26-000043]Further company coverage: XFOR.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J1VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925151","title":"X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925151?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:10","pubTimestamp":1778098208,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J1VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633318788","title":"X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633318788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633318788?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:16","pubTimestamp":1778066211,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals posted a net loss of $20.2 million, swinging from net income of $0.3 million a year earlier, as revenue fell 90.63% to $2.7 million.Operating loss widened to $20.3 million from $9.4 million as total operating expenses dropped 39.79% to $23 million.Research and development expense declined 16.22% to $15.5 million, while general and administrative expense slid 54% to $6.9 million.Other income, net fell 98.98% to $0.1 million on lower gains from fair-value adjustments to Class C warrants, partly offset by higher interest income.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDLRYWfP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182043","title":"BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633182043?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:15","pubTimestamp":1778066145,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16\n\n\nMay 06 (Reuters) - X4 Pharmaceuticals Q1 operating expenses USD 23.014 million.\n\nQ1 net income USD -20.241 million\nQ1 income from operations USD -20.306 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX827413:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633729182","title":"X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633729182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633729182?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:15","pubTimestamp":1778066100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUAB7WLY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633248182","title":"X4 Pharmaceuticals Q1 Operating Expenses USD 23.014 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633248182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633248182?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:15","pubTimestamp":1778066100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX827413:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631237590","title":"X4 says EU approves Xolremdi for WHIM syndrome treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2631237590","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631237590?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:04","pubTimestamp":1777460663,"startTime":"0","endTime":"0","summary":"European Commission granted marketing authorization for X4 Pharmaceuticals’ XOLREMDI  to treat WHIM syndrome in European Union.Norgine will lead commercialization in Europe under a licensing and supply agreement signed in January 2025.Deal terms include up to EUR 226 million in regulatory and commercial milestones.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL8pYcLw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","BK4139","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","BK4585","LU0314104364.USD","IE00BN0W2V16.EUR","XFOR","IE00BN0W2T93.GBP","NDAQ","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631590631","title":"X4 Pharmaceuticals Announces European Commission Approval of Xolremdi® (Mavorixafor), the First and Only Authorized Treatment for Patients With Whim Syndrome in the European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2631590631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631590631?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:00","pubTimestamp":1777460403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUA3BBGSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630392813","title":"X4 Pharmaceuticals Inc  expected to post a loss of 20 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2630392813","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630392813?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:19","pubTimestamp":1777295947,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals Inc  expected to post a loss of20cents a share - Earnings Preview X4 Pharmaceuticals Inc XFOR.OQ XFOR.O is expected to  show a fall in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL8N41A1EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624492544","title":"BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624492544","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624492544?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:18","pubTimestamp":1775078295,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 1 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ L","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUAHQQS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624502541","title":"X4 Pharmaceuticals issues inducement stock options for 32,000 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624502541?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:32","pubTimestamp":1775075536,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals issued inducement stock options covering 32,000 shares, effective March 31, 2026.Options carry a 10-year term with an exercise price of $4.13 per share.Vesting schedule sets 25% after 12 months with remaining balance vesting monthly over next 36 months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4Skjl7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BN0W2V16.EUR","XFOR","SG9999014005.SGD","BK4588","BK4112","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620369287","title":"X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2620369287","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620369287?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:46","pubTimestamp":1774010774,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals will hold its annual meeting virtually on May 11, 2026.Shareholders will vote to elect three Class III director nominees to serve until the 2029 annual meeting.Items up for approval include a 1.5 million-share increase under the Second Amended and Restated 2017 Equity Incentive Plan.A non-binding advisory vote on named executive officer compensation is also scheduled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL2SVM55:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620258086","title":"Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258086?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:40","pubTimestamp":1773834015,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report), Boston ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-x4-pharmaceuticals-xfor-boston-scientific-bsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-x4-pharmaceuticals-xfor-boston-scientific-bsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0128526141.USD","HCSG","LU0267386448.USD","LU1791710582.SGD","SG9999001176.USD","LU1791710400.SGD","LU2506952097.USD","LU0353189763.USD","BK4137","LU1718418525.SGD","BSX","BK4581","LU1720051108.HKD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0823417653.USD","LU1989764664.SGD","XLV","LU2491049909.HKD","LU0238689110.USD","LU2265009873.SGD","LU1989764748.USD","IE0002141913.USD","LU2491050154.USD","LU0345769631.USD","LU1061106388.HKD","LU1366192091.USD","XFOR","BK4139","LU1023059063.AUD","IE0009355771.USD","LU0187121727.USD","LU0823416689.USD","LU2506952170.USD","LU0266013472.USD","LU0823417737.USD","LABU","LU1291159041.SGD","XBI","LU0882574055.USD","BK4504","LU2087625088.SGD","SGXZ57979304.SGD","LU1720051017.SGD","LU2362541273.HKD","LU0345769128.USD","LU0950375773.USD","LU0048584097.USD","LU1153585028.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426032","title":"X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426032?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUAVCPTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429894","title":"Rpt-X4 Pharmaceuticals Q4 EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429894?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX6E47AA:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429889","title":"X4 Pharmaceuticals Inc - Cash Runway Expected Through 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429889?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX6E47AA:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620142989","title":"X4 Pharmaceuticals Inc - Global 4Ward Phase 3 Chronic Neutropenia Trial on Track to Complete Enrollment in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620142989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620142989?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX6E47AA:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426926","title":"X4 Pharmaceuticals FY 2025 net loss widens 111.2% to USD 79.2 million as revenue rises 1,250% to USD 35.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426926","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426926?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:02","pubTimestamp":1773745363,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals published its annual report on Form 10-K for FY 2025, reporting revenue of USD 35.1 million. FY 2025 net loss was USD 79.2 million, while loss from operations was USD 86.9 million. FY 2025 research and development expense fell 10.9% to USD 72.7 million, primarily due to lower spending following 2025 strategic restructurings, partially offset by higher clinical costs for the Phase 3 4WARD trial. FY 2025 general and administrative expense decreased 29.4% to USD 43.5 million, driven by lower headcount and reduced sales and marketing spending versus the prior year’s XOLREMDI launch costs. Management said cash, cash equivalents and restricted cash totaled USD 217.9 million at year-end, and expects cash, cash equivalents and marketable securities to fund operations for at least the next 12 months, while noting full enrollment in the 4WARD trial is expected in Q3 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9sTDw2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618257629","title":"X4 Pharmaceuticals Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2618257629","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618257629?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:16","pubTimestamp":1773062160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XFOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 09:16 ET (13:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.x4pharma.com","stockEarnings":[{"period":"1week","weight":0.0333},{"period":"1month","weight":0.0585},{"period":"3month","weight":0.2653},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2994},{"period":"ytd","weight":0.085}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.010739},{"month":2,"riseRate":0.555556,"avgChangeRate":0.007538},{"month":3,"riseRate":0.555556,"avgChangeRate":0.084933},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.024796},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028888},{"month":6,"riseRate":0.125,"avgChangeRate":-0.268932},{"month":7,"riseRate":0.25,"avgChangeRate":-0.039863},{"month":8,"riseRate":0.375,"avgChangeRate":0.07504},{"month":9,"riseRate":0.25,"avgChangeRate":-0.001382},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084011},{"month":11,"riseRate":0.25,"avgChangeRate":0.161316},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.049964}],"exchange":"NASDAQ","name":"X4 Pharmaceuticals Inc","nameEN":"X4 Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"X4 Pharmaceuticals Inc,XFOR,X4 Pharmaceuticals Inc股票,X4 Pharmaceuticals Inc股票老虎,X4 Pharmaceuticals Inc股票老虎国际,X4 Pharmaceuticals Inc行情,X4 Pharmaceuticals Inc股票行情,X4 Pharmaceuticals Inc股价,X4 Pharmaceuticals Inc股市,X4 Pharmaceuticals Inc股票价格,X4 Pharmaceuticals Inc股票交易,X4 Pharmaceuticals Inc股票购买,X4 Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction